Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $8.96, but opened at $10.03. Intellia Therapeutics shares last traded at $9.89, with a volume of 2,272,951 shares.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wells Fargo & Company decreased their target price on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Truist Financial reduced their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.95.
View Our Latest Analysis on NTLA
Intellia Therapeutics Stock Performance
The firm has a 50 day moving average price of $8.14 and a two-hundred day moving average price of $9.74. The company has a market capitalization of $1.02 billion, a P/E ratio of -1.81 and a beta of 2.14.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. The firm's quarterly revenue was down 42.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.12) EPS. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.
Institutional Investors Weigh In On Intellia Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its holdings in Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after purchasing an additional 3,596 shares during the last quarter. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $4,793,000. Baker BROS. Advisors LP acquired a new stake in Intellia Therapeutics during the fourth quarter worth approximately $7,510,000. Finally, XTX Topco Ltd increased its stake in Intellia Therapeutics by 194.6% in the fourth quarter. XTX Topco Ltd now owns 43,908 shares of the company's stock valued at $512,000 after purchasing an additional 29,006 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
